DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Third Quarterly Performance Report (QPR) Released
August 2, 2017

The QPR contains revenue, expenditure and performance measure information from the Department of Health. Continue reading


CDC’s National Center for Health Statistics CEU
July 31, 2017

E-Learning Tool: Applying Best Practices for Reporting Medical and Health Information on Birth Certificates Continue reading